<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78883">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01851746</url>
  </required_header>
  <id_info>
    <org_study_id>CHB2013</org_study_id>
    <nct_id>NCT01851746</nct_id>
  </id_info>
  <brief_title>A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (&gt;6 Months) Relapsed Ovarian Cancer</brief_title>
  <official_title>A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (&gt;6 Months) Relapsed Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and security of lobaplatin
      combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evidence of  the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.</measure>
    <time_frame>from pre-chemotherapy to 4-6 weeks post-chemotherapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood routine, urine routine,  hepatic and kidney function, electrolyte, ECG, CT,MRI</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Boold,Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        residents of a certain town
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age between 18 and  70 years old

          2. singed the information consent form

          3. Expected survival time &gt;3 months

          4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy
             and without cytoreductive surgery indications.

        Exclusion Criteria:

          1. Recurrence within 6 months after receiving initial platinum-based chemotherapy

          2. without radiographic evidence for tumor recurrence

          3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong-bing Cai, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 9, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan University</investigator_affiliation>
    <investigator_full_name>HB Cai</investigator_full_name>
    <investigator_title>Director of gynecologic oncology department of Zhongnan Hospital of Wuhan University</investigator_title>
  </responsible_party>
  <keyword>recurrent ovarian cancer</keyword>
  <keyword>lobaplatin</keyword>
  <keyword>docetaxel</keyword>
  <keyword>carboplatin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
